Literature DB >> 15625103

Inhibition of cardiac myofibroblast formation and collagen synthesis by activation and overexpression of adenylyl cyclase.

James S Swaney1, David M Roth, Erik R Olson, Jennifer E Naugle, J Gary Meszaros, Paul A Insel.   

Abstract

Transformation of fibroblasts to myofibroblasts, characterized by expression of alpha-smooth muscle actin (alpha-SMA) and production of extracellular matrix (ECM) components, is a key event in connective tissue remodeling. Approaches to inhibit this transformation are needed in tissues, such as the heart, where excessive ECM production by cardiac fibroblasts (CFs) causes fibrosis, myocardial stiffening, and cardiac dysfunction. We tested whether adenylyl cyclase (AC) activation (increased cAMP levels) modulates the transformation of adult rat CF to myofibroblasts, as assessed by immunofluorescent microscopy, immunoblotting, and collagen synthesis. A 24-h incubation of CF with TGF-beta or angiotensin II increased alpha-SMA expression, which was inhibited by the AC agonist forskolin and a cAMP analog that activates protein kinase A. Treatment with forskolin blunted serum-, TGF-beta-, and angiotensin II-stimulated collagen synthesis. CFs engineered to overexpress type 6 AC had enhanced forskolin-promoted cAMP formation, greater inhibition by forskolin of TGF-beta-stimulated alpha-SMA expression, and a decrease in the EC(50) of forskolin to reduce serum-stimulated collagen synthesis. The AC stimulatory agonist adrenomedullin inhibited collagen synthesis in CF that overexpressed AC6 but not in controls. Thus, AC stimulation blunts collagen synthesis and, in parallel, the transformation of adult rat CF to myofibroblasts. AC overexpression enhances these effects, "uncovering" an inhibition by adrenomedullin. These findings implicate cAMP as an inhibitor of ECM formation by means of blockade of the transformation of CF to myofibroblasts and suggest that increasing AC expression, thereby enhancing cAMP generation through stimulation of receptors expressed on CF, could provide a means to attenuate and prevent cardiac fibrosis and its sequelae.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15625103      PMCID: PMC544320          DOI: 10.1073/pnas.0408704102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  52 in total

1.  The cardiac fibroblast, another therapeutic target for mending the broken heart?

Authors:  Carlin S Long; R Dale Brown
Journal:  J Mol Cell Cardiol       Date:  2002-10       Impact factor: 5.000

2.  A novel Epac-specific cAMP analogue demonstrates independent regulation of Rap1 and ERK.

Authors:  Jorrit M Enserink; Anne E Christensen; Johan de Rooij; Miranda van Triest; Frank Schwede; Hans Gottfried Genieser; Stein O Døskeland; Jonathan L Blank; Johannes L Bos
Journal:  Nat Cell Biol       Date:  2002-11       Impact factor: 28.824

3.  Smad3 mediates transforming growth factor-beta-induced alpha-smooth muscle actin expression.

Authors:  Biao Hu; Zhe Wu; Sem H Phan
Journal:  Am J Respir Cell Mol Biol       Date:  2003-04-17       Impact factor: 6.914

4.  Adrenomedullin inhibits angiotensin AT1A receptor expression and function in cardiac fibroblasts.

Authors:  Dominic J Autelitano; Rebecca Ridings; Luisa Pipolo; Walter G Thomas
Journal:  Regul Pept       Date:  2003-04-15

5.  Angiotensin II enhances adenylyl cyclase signaling via Ca2+/calmodulin. Gq-Gs cross-talk regulates collagen production in cardiac fibroblasts.

Authors:  Rennolds S Ostrom; Jennifer E Naugle; Miki Hase; Caroline Gregorian; James S Swaney; Paul A Insel; Laurence L Brunton; J Gary Meszaros
Journal:  J Biol Chem       Date:  2003-04-23       Impact factor: 5.157

6.  Prostaglandin E2 inhibits fibroblast to myofibroblast transition via E. prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation.

Authors:  Jill E Kolodsick; Marc Peters-Golden; Jose Larios; Galen B Toews; Victor J Thannickal; Bethany B Moore
Journal:  Am J Respir Cell Mol Biol       Date:  2003-05-08       Impact factor: 6.914

7.  Mechanical force regulation of myofibroblast differentiation in cardiac fibroblasts.

Authors:  J Wang; H Chen; A Seth; C A McCulloch
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-07-03       Impact factor: 4.733

8.  Cyclic adenosine 3',5'-monophosphate-elevating agents inhibit transforming growth factor-beta-induced SMAD3/4-dependent transcription via a protein kinase A-dependent mechanism.

Authors:  Meinhard Schiller; Frank Verrecchia; Alain Mauviel
Journal:  Oncogene       Date:  2003-12-04       Impact factor: 9.867

9.  Glucocorticoids modulate TGF-beta production by human fetal lung fibroblasts.

Authors:  Fu-Qiang Wen; Tadashi Kohyama; C Magnus Sköld; Yun Kiu Zhu; Xiangde Liu; Debra J Romberger; Julie Stoner; Stephen I Rennard
Journal:  Inflammation       Date:  2003-02       Impact factor: 4.092

10.  Effects of tacrolimus and dexamethasone on tubulointerstitial fibrosis in mercuric chloride treated Brown Norway rats.

Authors:  Kazuhiko Suzuki; Tomomichi Kanabayashi; Hiroyuki Nakayama; Kunio Doi
Journal:  Exp Toxicol Pathol       Date:  2003-09
View more
  97 in total

1.  Genistein alleviates pressure overload-induced cardiac dysfunction and interstitial fibrosis in mice.

Authors:  Wei Qin; Ning Du; Longyin Zhang; Xianxian Wu; Yingying Hu; Xiaoguang Li; Nannan Shen; Yang Li; Baofeng Yang; Chaoqian Xu; Zhiwei Fang; Yanjie Lu; Yong Zhang; Zhimin Du
Journal:  Br J Pharmacol       Date:  2015-01-13       Impact factor: 8.739

2.  ATP released from cardiac fibroblasts via connexin hemichannels activates profibrotic P2Y2 receptors.

Authors:  David Lu; Sahar Soleymani; Rohit Madakshire; Paul A Insel
Journal:  FASEB J       Date:  2012-03-13       Impact factor: 5.191

3.  Cardiac lineage protein-1 (CLP-1) regulates cardiac remodeling via transcriptional modulation of diverse hypertrophic and fibrotic responses and angiotensin II-transforming growth factor β (TGF-β1) signaling axis.

Authors:  Eduardo Mascareno; Josephine Galatioto; Inna Rozenberg; Louis Salciccioli; Haroon Kamran; Jason M Lazar; Fang Liu; Thierry Pedrazzini; M A Q Siddiqui
Journal:  J Biol Chem       Date:  2012-02-03       Impact factor: 5.157

4.  A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model.

Authors:  J S Swaney; C Chapman; L D Correa; K J Stebbins; R A Bundey; P C Prodanovich; P Fagan; C S Baccei; A M Santini; J H Hutchinson; T J Seiders; T A Parr; P Prasit; J F Evans; D S Lorrain
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

5.  A murine model of alcoholic cardiomyopathy: a role for zinc and metallothionein in fibrosis.

Authors:  W Keith Jones
Journal:  Am J Pathol       Date:  2005-08       Impact factor: 4.307

6.  Iron-loaded cardiac myocytes stimulate cardiac myofibroblast DNA synthesis.

Authors:  Ying Liu; Douglas M Templeton
Journal:  Mol Cell Biochem       Date:  2006-01       Impact factor: 3.396

7.  Uridine triphosphate (UTP) induces profibrotic responses in cardiac fibroblasts by activation of P2Y2 receptors.

Authors:  Oscar O Braun; David Lu; Nakon Aroonsakool; Paul A Insel
Journal:  J Mol Cell Cardiol       Date:  2010-05-13       Impact factor: 5.000

8.  Adenylyl cyclase 6 deletion reduces left ventricular hypertrophy, dilation, dysfunction, and fibrosis in pressure-overloaded female mice.

Authors:  Tong Tang; N Chin Lai; H Kirk Hammond; David M Roth; Yuan Yang; Tracy Guo; Mei Hua Gao
Journal:  J Am Coll Cardiol       Date:  2010-04-06       Impact factor: 24.094

9.  Regulation of myofibroblast differentiation and bleomycin-induced pulmonary fibrosis by adrenomedullin.

Authors:  Jacob Kach; Nathan Sandbo; Nan Sethakorn; Jesse Williams; Eleanor B Reed; Jennifer La; Xinyong Tian; Susan D Brain; Kavitha Rajendran; Ramaswamy Krishnan; Anne I Sperling; Konstantin Birukov; Nickolai O Dulin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-04-12       Impact factor: 5.464

10.  Curcumin reduces cardiac fibrosis by inhibiting myofibroblast differentiation and decreasing transforming growth factor β1 and matrix metalloproteinase 9 / tissue inhibitor of metalloproteinase 1.

Authors:  Jin Ma; Shi-Yu Ma; Chun-Hua Ding
Journal:  Chin J Integr Med       Date:  2016-03-08       Impact factor: 1.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.